On July 28, the China Drug Price Registration System (China Drug Registration) launched its medical device segment and issued the first batch of price registration certificates to eight companies, including Beijing Huatan Biotechnology, Shanghai Xinwei Medical, and others. The platform, jointly sponsored by the National Healthcare Security Administration and the Beijing Municipal Government and organized by the Xicheng District Government, aims to facilitate market price registration outside the medical insurance payment system. Supported by the Ministry of Commerce's Foreign Trade Development Bureau, the system will also organize domestic medical device firms to participate in international medical exhibitions in Poland and Bangladesh.
In the first half of 2026, China's pharmaceutical distribution industry recorded a market size of about 1.54 trillion RMB, up approximately 4% year on year. The sector is accelerating its transformation toward intensification and specialization. High-end cold chain logistics has emerged as a profit growth driver, with leading enterprises deploying multi-temperature zone smart warehouses nationwide. As digital and intelligent upgrades become widespread, AI scheduling, unmanned warehouses, and full-chain temperature and humidity tracking have become standard.
Wondfo Biotech, founded in 2000, announced a share repurchase of 30 million to 60 million yuan for equity incentives, at a cap of 27.06 yuan per share. Chairman Wang Jihua plans to increase his holdings by 20 million to 40 million yuan. Wang directly holds 10.6% of the company, and together with his spouse holds 31.5%. The repurchase will lift restricted shares from 8.12% to 8.60% or 8.36%.